SCHEMBL4690432

SCHEMBL4690432

Cc1ccc(-c2ccoc2C(=O)NC2CCN(CCC3(CCNC(=O)O)CCCCC3)CC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 5/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
MAPK14 Q16539 1/20 0.37
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
ALDH1A1 P00352 3/20 0.35
HRH3 Q9Y5N1 1/20 0.35
LMNA P02545 1/20 0.35
CNR1 P21554 1/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
MEN1 O00255 2/20 0.34
S1PR1 P21453 1/20 0.34
POLB P06746 1/20 0.34
CYP1A2 P05177 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4693190 0.91 L3MBTL1 (0.39) MCHR1L3MBTL1MAPK14CARM1PRMT6
SCHEMBL4687554 0.91 L3MBTL1 (0.38) MCHR1L3MBTL1CARM1PRMT6ALDH1A1
SCHEMBL4688285 0.90 L3MBTL1 (0.36) MCHR1L3MBTL1CARM1PRMT6ALDH1A1
SCHEMBL4691176 0.90 KCNA3 (0.38) MCHR1L3MBTL1MAPK14ALDH1A1HRH3
SCHEMBL5107097 0.89 L3MBTL1 (0.36) MCHR1L3MBTL1MAPK14CARM1PRMT6
SCHEMBL4691461 0.88 MCHR1 (0.38) MCHR1L3MBTL1MAPK14ALDH1A1HRH3
SCHEMBL4690005 0.88 PDE10A (0.40) L3MBTL1MAPK14CARM1PRMT6ALDH1A1
SCHEMBL4686722 0.88 L3MBTL1 (0.36) MCHR1L3MBTL1MAPK14CARM1PRMT6
SCHEMBL1848745 0.88 ALDH1A1 (0.41) MCHR1L3MBTL1CARM1PRMT6ALDH1A1
SCHEMBL4690036 0.86 MCHR1 (0.36) MCHR1L3MBTL1ALDH1A1HRH3CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1443046-B1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME KYORIN SEIYAKU KK (JP) 2008-12-17 EP disclosed
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. 2008-08-14 US disclosed
US-7375115-B2 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-05-20 US disclosed
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2005-04-21 US disclosed
EP-1443046-A1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME Kyorin Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same CYP4F2, CYP1A2, CYP4B1 MCHR1 1825/4885L3MBTL1 4882/4885MAPK14 3040/4885
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same OPRM1, OPRD1, HRH4 MCHR1 187/4885L3MBTL1 3273/4885MAPK14 3081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.